Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.42 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8575036 | 1.00 | KMT2A (0.49) | KMT2ATLR2FABP5FABP7DPP7 | |
| Hydrochloric Acid SCHEMBL13858072 | 0.99 | KMT2A (0.48) | KMT2ATLR2FABP5FABP7DPP7 | |
| Hydrochloric Acid SCHEMBL6518503 | 0.97 | KMT2A (0.49) | KMT2ATLR2FABP5FABP7DPP7 | |
| SCHEMBL17941346 | 0.95 | KMT2A (0.51) | KMT2ATLR2FABP5FABP7DPP7 | |
| SCHEMBL15674719 | 0.94 | KMT2A (0.44) | KMT2ATLR2FABP5FABP7DPP7 | |
| Hydrochloric Acid SCHEMBL4163755 | 0.93 | KMT2A (0.50) | KMT2ATLR2FABP5FABP7DPP7 | |
| SCHEMBL1901193 | 0.89 | KMT2A (0.53) | KMT2ATLR2FABP5FABP7CA1 | |
| SCHEMBL3842242 | 0.89 | KMT2A (0.46) | KMT2ATLR2FABP5FABP7DPP7 | |
| Hydrochloric Acid SCHEMBL6366019 | 0.88 | KMT2A (0.52) | KMT2ATLR2FABP5FABP7CA1 | |
| Bromide SCHEMBL16269651 | 0.88 | KMT2A (0.52) | KMT2ATLR2FABP5FABP7CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| EP-1625138-A2 | PROTECTED MONOMERS | Alnylam Pharmaceuticals Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | KMT2A 1569/4885TLR2 1800/4885FABP5 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.